Pfizer Hosts Annual Meeting Of Shareholders
Declares 24-Cent Second-Quarter 2013 Dividend
NEW YORK -- April 25, 2013
The board of directors of Pfizer Inc. today declared a 24-cent second-quarter
2013 dividend on the company’s common stock, payable June 4, 2013, to
shareholders of record at the close of business on May 10, 2013. The
second-quarter 2013 cash dividend will be the 298^th consecutive quarterly
dividend paid by Pfizer.
“Through dividends and share repurchases, we returned approximately $15
billion to our shareholders in 2012,” said Ian Read, chairman and chief
executive officer, Pfizer. “In 2013, we are continuing to take actions to
increase shareholder value, including our dividend increase announced in
December 2012, our continued share repurchase activity and the successful
completion of the IPO of a 19.8% interest in Zoetis in February 2013.”
Preliminary results from the meeting indicate that the company’s 13 continuing
directors were re-elected to one-year terms and that shareholders ratifiedthe
selection of KPMG LLP as Pfizer’s independent registered public accounting
firm for the 2013 fiscal year. In addition, shareholders voted in support of a
board-sponsored proposal to approve, on an advisory basis, the compensation of
the company’s named executive officers.
In other voting, two shareholder proposals were not approved by the
The final results are subject to verification by the independent election
inspectors. The final results will be reported in a Form 8-K to be filed by
Pfizer with the Securities and Exchange Commission in the next few days.
Pfizer Inc.: Working together for a healthier world®
At Pfizer, we apply science and our global resources to bring therapies to
people that extend and significantly improve their lives. We strive to set the
standard for quality, safety and value in the discovery, development and
manufacture of health care products. Our global portfolio includes medicines
and vaccines as well as many of the world's best-known consumer health care
products. Every day, Pfizer colleagues work across developed and emerging
markets to advance wellness, prevention, treatments and cures that challenge
the most feared diseases of our time. Consistent with our responsibility as
one of the world's premier innovative biopharmaceutical companies, we
collaborate with health care providers, governments and local communities to
support and expand access to reliable, affordable health care around the
world. For more than 150 years, Pfizer has worked to make a difference for all
who rely on us. To learn more, please visit us at www.pfizer.com.
DISCLOSURE NOTICE: The information contained in this release is as of April
25, 2013. The Company assumes no obligation to update forward-looking
statements contained in this release as a result of new information or future
events or developments.
This release contains forward-looking information about the Company’s actions
to increase shareholder value, including with respect to dividends and share
repurchases, that involves substantial risks and uncertainties. A description
of these risks and uncertainties can be found in the Company’s Annual Report
on Form 10-K/A for the fiscal year ended December 31, 2012 and in its reports
on Forms 10-Q and 8-K.
Joan Campion, 212-733-2798
Suzanne Harnett, 212-733-8009
Press spacebar to pause and continue. Press esc to stop.